Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2018

01-04-2018 | Original article

Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience

Authors: Masaya Saito, Atsushi Komatsuda, Ryuta Sato, Ayano Saito, Hajime Kaga, Fumito Abe, Masato Sawamura, Mizuho Nara, Masaru Togashi, Shin Okuyama, Hideki Wakui, Naoto Takahashi

Published in: Clinical and Experimental Nephrology | Issue 2/2018

Login to get access

Abstract

Background

Three recent studies from the United States and China reported the clinicopathological features and short-term prognosis in patients with membranous nephropathy (MN) and crescents in the absence of secondary MN, anti-glomerular basement membrane (GBM) antibodies, and anti-neutrophil cytoplasmic antibodies (ANCA).

Methods

We compared clinicopathological and prognostic features in 16 MN patients with crescents (crescent group) and 38 MN patients without crescents (control group), in the absence of secondary MN, anti-GBM antibodies, and ANCA. Median follow-up periods in the crescent and control groups were 79 and 50 months, respectively.

Results

Decreased estimated glomerular filtration rates (<50 mL/min/1.73 m2), glomerulosclerosis, and moderate-to-severe interstitial fibrosis were more frequently observed in the crescent group than in the control group (P = 0.043, P = 0.004, and P = 0.035, respectively). Positive staining rates for glomerular IgG2 and IgG4 were significantly different between the 2 groups (P = 0.032, P = 0.006, respectively). Doubling of serum creatinine during follow-up was more frequently observed in the crescent group than in the control group (P = 0.002), although approximately two-thirds of patients in the crescent group were treated with immunosuppressive therapy. Crescent formation and interstitial fibrosis were risks for doubling of serum creatinine [hazard ratio (HR) = 10.506, P = 0.012; HR = 1.140, P = 0.009, respectively].

Conclusions

This is the first Japanese study demonstrating significant differences in clinicopathological and prognostic features between the 2 groups. Most patients in the crescent group may develop a long-term decline in renal function despite immunosuppressive therapy.
Literature
2.
go back to reference Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.CrossRefPubMedPubMedCentral Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-Type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.CrossRefPubMedPubMedCentral
3.
go back to reference Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19:653–60.CrossRefPubMed Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S. Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol. 2015;19:653–60.CrossRefPubMed
4.
go back to reference Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS ONE. 2015;10:e0138841.CrossRefPubMedPubMedCentral Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the glomeruli of Japanese patients with idiopathic membranous nephropathy. PLoS ONE. 2015;10:e0138841.CrossRefPubMedPubMedCentral
6.
go back to reference Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51:270–6.CrossRefPubMed Imai H, Hamai K, Komatsuda A, Ohtani H, Miura AB. IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis. Kidney Int. 1997;51:270–6.CrossRefPubMed
7.
go back to reference Omokawa A, Komatsuda A, Nara M, Fujiwara S, Sato R, Togashi M, et al. Distribution of IgG subclass deposits in patients with membranous nephropathy and anti-U1 ribonucleoprotein antibody. Nephrol Dial Transplant. 2012;27:1937–41.CrossRefPubMed Omokawa A, Komatsuda A, Nara M, Fujiwara S, Sato R, Togashi M, et al. Distribution of IgG subclass deposits in patients with membranous nephropathy and anti-U1 ribonucleoprotein antibody. Nephrol Dial Transplant. 2012;27:1937–41.CrossRefPubMed
8.
go back to reference Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.CrossRefPubMed Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002;39:706–12.CrossRefPubMed
9.
go back to reference Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19:574–9.CrossRefPubMed Ohtani H, Wakui H, Komatsuda A, Okuyama S, Masai R, Maki N, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant. 2004;19:574–9.CrossRefPubMed
10.
go back to reference Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13:723–9.CrossRefPubMed Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014;13:723–9.CrossRefPubMed
11.
go back to reference Basford AW, Lewis J, Dwyer JP, Fogo AB. Membranous nephropathy with crescents. J Am Soc Nephrol. 2011;22:1804–8.CrossRefPubMed Basford AW, Lewis J, Dwyer JP, Fogo AB. Membranous nephropathy with crescents. J Am Soc Nephrol. 2011;22:1804–8.CrossRefPubMed
12.
go back to reference Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D’Agati VD, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299–308.CrossRefPubMedPubMedCentral Nasr SH, Said SM, Valeri AM, Stokes MB, Masani NN, D’Agati VD, et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009;4:299–308.CrossRefPubMedPubMedCentral
13.
go back to reference Barrett CM, Troxell ML, Larsen CP, Houghton DC. Membranous glomerulonephritis with crescents. Int Urol Nephrol. 2014;46:963–71.CrossRefPubMed Barrett CM, Troxell ML, Larsen CP, Houghton DC. Membranous glomerulonephritis with crescents. Int Urol Nephrol. 2014;46:963–71.CrossRefPubMed
14.
15.
go back to reference Tse WY, Howie AJ, Adu D, Savage CO, Richards NT, Wheeler DC, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant. 1997;12:1017–27.CrossRefPubMed Tse WY, Howie AJ, Adu D, Savage CO, Richards NT, Wheeler DC, et al. Association of vasculitic glomerulonephritis with membranous nephropathy: a report of 10 cases. Nephrol Dial Transplant. 1997;12:1017–27.CrossRefPubMed
16.
go back to reference Arrizabalaga P, Boix AS, Rabassa AT, Tey AD, Torrellas LR. Monoclonal antibody analysis of crescentic membranous glomerulonephropathy. Am J Nephrol. 1998;18:77–82.CrossRefPubMed Arrizabalaga P, Boix AS, Rabassa AT, Tey AD, Torrellas LR. Monoclonal antibody analysis of crescentic membranous glomerulonephropathy. Am J Nephrol. 1998;18:77–82.CrossRefPubMed
17.
go back to reference Unver S, Haholu A, Atasoyu EM, Karatas M, Akcan R, Evrenkaya TR. A rare complication of idiopathic membranous nephropathy: crescent transformation. Ren Fail. 2008;30:573–5.CrossRefPubMed Unver S, Haholu A, Atasoyu EM, Karatas M, Akcan R, Evrenkaya TR. A rare complication of idiopathic membranous nephropathy: crescent transformation. Ren Fail. 2008;30:573–5.CrossRefPubMed
18.
go back to reference Gadonski G, Poli-de-Figueiredo CE, Fervenza FC, Singh AK, Tettamanzy FM, Antonello IC, et al. Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy. Nephron Clin Pract. 2010;115:c100–6.CrossRefPubMedPubMedCentral Gadonski G, Poli-de-Figueiredo CE, Fervenza FC, Singh AK, Tettamanzy FM, Antonello IC, et al. Rapidly deteriorating kidney function in a young man previously diagnosed with membranous nephropathy. Nephron Clin Pract. 2010;115:c100–6.CrossRefPubMedPubMedCentral
19.
go back to reference Rodriguez EF, Nasr SH, Larsen CP, Sethi S, Fidler ME, Cornell LD. Membranous nephropathy with crescents: a series of 19 cases. Am J Kidney Dis. 2014;64:66–73.CrossRefPubMed Rodriguez EF, Nasr SH, Larsen CP, Sethi S, Fidler ME, Cornell LD. Membranous nephropathy with crescents: a series of 19 cases. Am J Kidney Dis. 2014;64:66–73.CrossRefPubMed
20.
go back to reference Wang J, Zhu P, Cui Z, Qu Z, Zhang Y, Wang F, et al. Clinical features and outcomes in patients with membranous nephropathy and crescent formation. Medicine. 2015;94:e2294.CrossRefPubMedPubMedCentral Wang J, Zhu P, Cui Z, Qu Z, Zhang Y, Wang F, et al. Clinical features and outcomes in patients with membranous nephropathy and crescent formation. Medicine. 2015;94:e2294.CrossRefPubMedPubMedCentral
21.
go back to reference Qian Y, Zuo K, Shijun L, Li X, Zeng C, Liu Z, et al. Clinicopathological analysis of membranous nephropathy with crescents. Int J Clin Pathol. 2016;9:1947–53. Qian Y, Zuo K, Shijun L, Li X, Zeng C, Liu Z, et al. Clinicopathological analysis of membranous nephropathy with crescents. Int J Clin Pathol. 2016;9:1947–53.
22.
go back to reference Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
23.
go back to reference Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26:2526–32.CrossRefPubMed Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant. 2011;26:2526–32.CrossRefPubMed
24.
go back to reference Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, et al. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol. 2017;21:212–27.CrossRefPubMed Ozawa M, Komatsuda A, Ohtani H, Nara M, Sato R, Togashi M, et al. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol. 2017;21:212–27.CrossRefPubMed
25.
go back to reference Komatsuda A, Masai R, Ohtani H, Maki N, Sawada K, Wakui H. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant. 2008;23:3888–94.CrossRefPubMed Komatsuda A, Masai R, Ohtani H, Maki N, Sawada K, Wakui H. Monoclonal immunoglobulin deposition disease associated with membranous features. Nephrol Dial Transplant. 2008;23:3888–94.CrossRefPubMed
26.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:186–97.CrossRef Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl. 2012;2:186–97.CrossRef
27.
go back to reference Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall’s pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205–51.
Metadata
Title
Clinicopathological and long-term prognostic features of membranous nephropathy with crescents: a Japanese single-center experience
Authors
Masaya Saito
Atsushi Komatsuda
Ryuta Sato
Ayano Saito
Hajime Kaga
Fumito Abe
Masato Sawamura
Mizuho Nara
Masaru Togashi
Shin Okuyama
Hideki Wakui
Naoto Takahashi
Publication date
01-04-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 2/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1465-y

Other articles of this Issue 2/2018

Clinical and Experimental Nephrology 2/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.